Debt-to-equity in % of REGENEREX PHARMA, INC. from Q4 2019 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
REGENEREX PHARMA, INC. quarterly Debt-to-equity history and change rate from Q4 2019 to Q3 2025.
  • REGENEREX PHARMA, INC. Debt-to-equity for the quarter ending 30 Sep 2025 was -118 %, a 0.26% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

REGENEREX PHARMA, INC. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -118 -0.31 -0.26% 30 Sep 2025
Q2 2025 -118 +2.79 +2.31% 30 Jun 2025
Q1 2025 -118 +10.5 +8.16% 31 Mar 2025
Q4 2024 -115 +13.9 +10.7% 31 Dec 2024
Q3 2024 -118 +11.2 +8.72% 30 Sep 2024
Q2 2024 -121 +4.05 +3.25% 30 Jun 2024
Q1 2024 -128 -27.5 -27.3% 31 Mar 2024
Q4 2023 -129 -28.1 -27.7% 31 Dec 2023
Q3 2023 -129 -27.6 -27.3% 30 Sep 2023
Q2 2023 -125 -23.4 -23.1% 30 Jun 2023
Q1 2023 -101 +0.51 +0.5% 31 Mar 2023
Q4 2022 -101 +0.18 +0.18% 31 Dec 2022
Q3 2022 -101 +7.9 +7.24% 30 Sep 2022
Q2 2022 -101 +17.8 +14.9% 30 Jun 2022
Q1 2022 -101 +30.9 +23.4% 31 Mar 2022
Q4 2021 -101 +48.8 +32.5% 31 Dec 2021
Q3 2021 -109 +44 +28.7% 30 Sep 2021
Q2 2021 -119 +36.6 +23.5% 30 Jun 2021
Q1 2021 -132 +19.9 +13.1% 31 Mar 2021
Q4 2020 -150 -3.74 -2.56% 31 Dec 2020
Q3 2020 -153 30 Sep 2020
Q2 2020 -156 30 Jun 2020
Q1 2020 -152 31 Mar 2020
Q4 2019 -146 31 Dec 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.